ProMACE-CytaBOM

ProMACE-CytaBOM is a third-generation polychemotherapy regimen specifically designed for the treatment of aggressive, intermediate, and high-grade non-Hodgkin's lymphomas (NHL). It is an acronym for its constituent agents: Prednisone, Methotrexate, Adriamycin (Doxorubicin), Cyclophosphamide, and Etoposide (ProMACE), followed by Cytarabine (Cytozar), Bleomycin, Oncovin (Vincristine), and Methotrexate (CytaBOM). This combination regimen utilizes multiple mechanisms of action to target malignant lymphocytes, including DNA alkylation, antimetabolite interference with DNA synthesis, topoisomerase inhibition, and microtubule disruption. Developed primarily by researchers at the National Cancer Institute (NCI) in the 1980s, it demonstrated high complete response rates (60-86%) in clinical trials conducted by groups such as the Southwest Oncology Group (SWOG). While highly effective, the regimen is associated with significant hematologic toxicity and has largely been superseded in modern clinical practice by rituximab-containing protocols like R-CHOP.

Brand names

ProMACE-CytaBOM

Other names

ProMACE CytaBOMProMACE-CytoBOM